Have a feature idea you'd love to see implemented?
Let us know!
RARE Ultragenyx Pharmaceutical Inc
Price (delayed)
$46.02
Market cap
$4.25B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$6.39
Enterprise value
$4.13B
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of
Highlights
RARE's EPS is up by 29% year-on-year and by 11% since the previous quarter
Ultragenyx Pharmaceutical's debt has decreased by 27% YoY and by 9% from the previous quarter
The quick ratio has increased by 22% YoY but it has decreased by 21% QoQ
The equity has declined by 21% since the previous quarter
The gross margin has decreased by 4.9% YoY
Key stats
What are the main financial stats of RARE
Market
Valuations
Earnings
Shares outstanding
92.34M
Market cap
$4.25B
Enterprise value
$4.13B
Price to earnings (P/E)
N/A
Price to book (P/B)
12.48
Price to sales (P/S)
8.41
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.91
Revenue
$522.75M
EBIT
-$561.07M
EBITDA
-$526.39M
Free cash flow
-$427.03M
Per share
Balance sheet
Liquidity
EPS
-$6.39
Free cash flow per share
-$4.47
Book value per share
$3.69
Revenue per share
$5.47
TBVPS
$13.92
Total assets
$1.54B
Total liabilities
$1.18B
Debt
$34.08M
Equity
$339.83M
Working capital
$514.6M
Debt to equity
0.1
Current ratio
2.81
Quick ratio
2.51
Net debt/EBITDA
0.22
Margins
Efficiency
Dividend
EBITDA margin
-100.7%
Gross margin
86.2%
Net margin
-106.9%
Operating margin
-102.4%
Return on assets
-37.5%
Return on equity
-188.2%
Return on invested capital
-69.5%
Return on capital employed
-44.8%
Return on sales
-107.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RARE stock price
How has the Ultragenyx Pharmaceutical stock price performed over time
Intraday
-0.82%
1 week
-3.4%
1 month
-15.5%
1 year
18.49%
YTD
-3.76%
QTD
-17.16%
Financial performance
How have Ultragenyx Pharmaceutical's revenue and profit performed over time
Revenue
$522.75M
Gross profit
$450.86M
Operating income
-$535.53M
Net income
-$558.99M
Gross margin
86.2%
Net margin
-106.9%
Ultragenyx Pharmaceutical's net margin has increased by 31% YoY and by 12% from the previous quarter
The company's operating margin rose by 29% YoY and by 10% QoQ
The revenue rose by 27% year-on-year and by 9% since the previous quarter
The company's gross profit rose by 21% YoY and by 7% QoQ
Growth
What is Ultragenyx Pharmaceutical's growth rate over time
Valuation
What is Ultragenyx Pharmaceutical stock price valuation
P/E
N/A
P/B
12.48
P/S
8.41
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.91
RARE's EPS is up by 29% year-on-year and by 11% since the previous quarter
RARE's price to book (P/B) is 23% less than its last 4 quarters average of 16.2 and 7% less than its 5-year quarterly average of 13.4
The equity has declined by 21% since the previous quarter
The P/S is 45% lower than the 5-year quarterly average of 15.2 and 2.2% lower than the last 4 quarters average of 8.6
The revenue rose by 27% year-on-year and by 9% since the previous quarter
Efficiency
How efficient is Ultragenyx Pharmaceutical business performance
The ROE is up by 46% year-on-year and by 29% since the previous quarter
RARE's return on sales is up by 31% year-on-year and by 12% since the previous quarter
The return on assets has increased by 19% year-on-year and by 9% since the previous quarter
The company's return on invested capital rose by 10% QoQ and by 6% YoY
Dividends
What is RARE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RARE.
Financial health
How did Ultragenyx Pharmaceutical financials performed over time
The total assets is 30% more than the total liabilities
The total assets has grown by 24% YoY but it has contracted by 4.9% from the previous quarter
The quick ratio has increased by 22% YoY but it has decreased by 21% QoQ
Ultragenyx Pharmaceutical's debt is 90% less than its equity
Ultragenyx Pharmaceutical's debt to equity has plunged by 93% YoY but it has increased by 11% from the previous quarter
Ultragenyx Pharmaceutical's debt has decreased by 27% YoY and by 9% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.